> ## Content Index > Fetch the complete content index at: https://chivanta.com/llms.txt > Use this file to discover other available public pages before exploring further. # CAR-T Evolution (II): In Vivo CAR-T — Holy Grail or High-Stakes Bet? - URL: https://chivanta.com/in-vivo-car-t/ - Published: 2026-07-24T06:08:45.000Z - Updated: 2026-07-24T06:09:46.000Z - Description: $2.1B for a drug with zero efficacy data. $7B for another. In vivo CAR-T isn't a science story — it's a business model story. - Author: ShaoChi CHENG - Tags: Cell Therapy, Strategy, Business In mid-2025, AbbVie paid up to $2.1 billion to acquire a company called Capstan Therapeutics. At first glance, this looks like just another routine biotech acquisition; however, Capstan's lead asset, CPTX2309, had only just entered a Phase 1 trial in healthy volunteers at the time of the deal. There was no efficacy data to speak of. A company with essentially no clinical data commanded a $2.1 billion valuation, after having already raised over $300 million from top-tier pharma investors in its private rounds. The real story behind in vivo CAR-T isn't efficacy; it's the business model. --- ## Why Is the Market Chasing In Vivo CAR-T? The Answer Isn't Efficacy; It's Commercialization Autologous CAR-T, from Kymriah and Yescarta to today's approved products, has already proven it can change the course of disease and even cure some hematologic cancer patients. So the real bottleneck holding this field back from broader use isn't "does the drug work." It's "**can the drug be manufactured at scale, and can more patients actually access it.**" The commercial bottlenecks of the autologous model come down to: - **COGS structure**: Each patient needs its own manufacturing batch. Every patient's CAR-T product goes through cell isolation, genetic engineering, expansion, and quality control. It pushes per-dose cost into the hundreds of thousands of dollars. - **Vein-to-vein waiting time**: Collection to infusion typically takes 3–4 weeks. For late-stage patients with fast-progressing cancers, that waiting period is a source of lost efficacy. - **Accessibility constraints**: The entire process can only be executed at a small number of medical centers certified for cell therapy, which locks community hospitals out. If you want to dig deeper into the manufacturing challenges of CAR-T, you can read my earlier piece on that topic. [CAR-T Commercialization Challenges (I): Why Manufacturing Doesn’t Scale—The Vein-to-Vein Supply ChainCAR-T therapy has delivered remarkable clinical outcomes, yet scaling manufacturing remains one of the industry’s greatest challenges. Learn why CAR-T isn’t simply selling engineered cells—it’s selling an entire vein-to-vein supply chain![](https://chivanta.com/content/images/icon/chivanta-logo-only_a2-bc8ac809-3db9-4179-a192-0c0baac4e181.jpg)ChivantaShaoChi CHENG![](https://chivanta.com/content/images/thumbnail/photo-1615461066159-fea0960485d5-92886c1a-93ba-4ece-b2fa-2f12672901b5)](https://chivanta.com/car-t-manufacturing-challenges/) What in vivo CAR-T is trying to solve is a redefinition: turning CAR-T from a "one-batch-per-patient model" into an "standardized drug product." If T-cell genetic reprogramming can be done directly inside the patient's body, the entire workflow could simplify into a single pre-filled injection. Treatment is as simple as a vaccine shot, with a cost structure that looks like a traditional biologics rather than a cell therapy. That's precisely why AbbVie was willing to pay $2.1 billion for a Phase 1 asset: it wasn't pricing the molecule, it was pricing the platform and the addressable indications this business model could unlock once proven out. --- ## In Vivo CAR-T Delivery Systems: LNP, Lentiviral, AAV The technology race currently playing out is fundamentally a race in delivery vectors. **LNP-mRNA route** (represented by Capstan): lipid nanoparticles encapsulate mRNA to drive transient CAR expression in T cells. Expression is temporary, and CAR disappears after a few rounds of cell division. The upside of LNP-mRNA vectors is a strong safety profile; the downside is limited durability in body, which may not be sufficient for solid tumors or high-relapse-risk cancers that require sustained immune surveillance. This is also why Capstan chose to enter through autoimmune disease rather than challenging cancer treatment. Autoimmune indications want a one-time effect to "reset the immune system", which fits well with transient expression. **Lentiviral route** (represented by Umoja Biopharma and Interius BioTherapeutics): this path uses genomic integration, so CAR expression persists long-term in the T-cell genome, with durability closer to traditional autologous CAR-T. Interius's INT2104 uses an engineered third-generation lentiviral vector. Its VSV-G fusion protein is modified to remove its native receptor affinity and re-targeted using a specific binder molecule, homing in on CD7+ T/NK cells, which then produce a CD20-targeted CAR. This route is currently the leading approach for hematologic malignancy indications; Umoja and Interius are the two with candidates already in Phase 1 clinical trials. **AAV route**: currently more marginal, mainly constrained by payload capacity (CAR constructs are large, and AAV packaging is less flexible than LNP or lentivirus), though some companies are still experimenting with different configurations. --- ## In Vivo CAR-T Commercialization Bottlenecks and Challenges In vivo CAR-T faces these challenges in disease treatment. - **LNP targeting bottleneck**: LNPs adsorb ApoE in the bloodstream and tend to home to the liver by default. Whoever can engineer a non-liver-tropic LNP that precisely recognizes T cells will carve out a defining moat in an increasingly crowded field. Whoever solves this problem could have pricing power. This is exactly why delivery-vector companies, not single-disease drug assets, are likely to be the truly valuable targets in this wave. - **Transduction efficiency and drug dose**: the in vivo environment is far less controllable than ex vivo settings, so insufficient transduction efficiency leads directly into weaker efficacy. Immune backgrounds vary widely across patients, and designing a drug dose that delivers consistent efficacy across individuals is a major clinical design challenge. - **Durability and relapse risk**: mRNA's transient expression is a double-edged sword. It is an advantage in autoimmune disease, but a shortage in cancer treatment because of durability isn't high enough and rising relapse rates are real concerns. This also explains why different companies choose different first indications rather than going after every indication at once. - **REMS and safety oversight**: once CRS or ICANS is triggered, it's difficult to shut down in real time, which raises the bar for hospital-side monitoring and management capability. Notably, Interius's preclinical data showed no CRS or neurotoxicity signal in animal models. If that safety advantage also reveals in human data, it would directly affect whether this route can eventually move into community hospitals, breaking the constraint of treatment only in academic medical centers. In other words, it's the key determining whether CAR-T can overcome both manufacturing-facility and hospital-access constraints, and increases drug accessibility. --- ## Current Development Landscape for In Vivo CAR-T - **Capstan Therapeutics**: LNP-mRNA delivery platform, indication: autoimmune disease. Acquired by AbbVie for $2.1 billion in June 2025; CPTX2309 is currently in Phase 1. - **Interius BioTherapeutics**: Lentiviral delivery platform, indication: hematologic malignancy. Has received IND in 2024; INT2104 is currently in Phase 1. - **Umoja Biopharma**: Lentiviral delivery platform, indication: hematologic malignancy. UB-VV111 received FDA Fast Track designation in September 2025 and is currently in Phase 1. - **Kelonia Therapeutics**: Lentiviral delivery platform, indication: hematologic malignancy. KLN-1010 is currently in Phase 1\. After releasing Phase 1 interim data, Kelonia was acquired by Eli Lilly in 2026 for approximately $3.25 billion upfront in cash, with total around up to approximately $7 billion. - **Legend Biotech**: Lentiviral delivery platform, indication: hematologic malignancy. LB2501 (CD19/CD20 dual-targeted) is currently in Phase 1\. Legend Biotech already has an approved autologous CAR-T product, Carvykti, on the market. - **Tempest Therapeutics**: LNP-mRNA delivery platform, indication: neurological autoimmune diseases (myasthenia gravis, multiple sclerosis). TPST-4003 is currently in the **IIT** stage; first IIT is expected to launch in Q4 2026\. Tempest originally focused on developing small-molecule oncology drugs and entered CAR-T through acquisition. - **CSPC Pharmaceutical Group**: Lentiviral delivery platform, indication: hematologic malignancy. SYS6055 has received IND preparing to enter Phase 1. --- ## Chivanta Insights AbbVie's acquisition of Capstan shows that large pharma is now willing to pay near-blockbuster-level prices for an early-stage asset with no efficacy data yet. It is a betting on the idea that once the "delivery + editing platform" matures, it can be extended across different CAR constructs and indications. Beyond that, if in vivo CAR-T truly makes "customized cell therapy" into a "single pre-filled injection," the CDMOs and dedicated cell-therapy manufacturing facilities that currently depend on autologous CAR-T production certification will take a hit. These companies have invested significant capital in building facility over the past five years. That means, if in vivo CAR-T becomes viable, demand for that capacity could be cut off abruptly. I still hope for more effective, more accessible therapies to become reality for the patients who need it.